Oltipraz Targets AMPK Pathway to Cut Liver Fat in NAFLD Patients
A Phase 3 trial tests whether oltipraz, an AMPK activator, can safely reduce liver fat in non-alcoholic fatty liver disease.
Summary
Non-alcoholic fatty liver disease (NAFLD) is a major driver of metabolic dysfunction and accelerated aging. This completed Phase 3 trial evaluated oltipraz — a dithiolethione compound that activates AMPK — at two doses (90 mg and 120 mg) against placebo in NAFLD patients without cirrhosis. Oltipraz works through two complementary pathways: it activates AMPK to suppress S6K1, breaking the cycle of insulin resistance, and it inhibits the LXR-gamma/SREBP-1c axis to reduce fatty acid synthesis in the liver. By simultaneously addressing insulin resistance and lipogenesis, oltipraz targets the root metabolic drivers of liver fat accumulation. Given that NAFLD is closely tied to metabolic syndrome, cardiovascular risk, and biological aging, successful interventions like this could have meaningful healthspan implications for a rapidly growing patient population.
Detailed Summary
Non-alcoholic fatty liver disease has become one of the most prevalent metabolic conditions worldwide, affecting an estimated 25% of adults globally and carrying significant risks for progression to cirrhosis, liver cancer, cardiovascular disease, and premature mortality. Effective pharmacological treatments targeting the underlying metabolic mechanisms remain a major unmet clinical need.
This completed Phase 3 trial, sponsored by PharmaKing, investigated oltipraz — a member of the dithiolethione chemical class — for its ability to reduce liver fat in NAFLD patients who had not yet progressed to cirrhosis. The study compared two active doses (90 mg and 120 mg) against placebo to assess both efficacy and safety across a clinically relevant patient population.
Oltipraz operates through two well-characterized molecular pathways. First, it activates adenosine monophosphate-activated protein kinase (AMPK), which in turn inhibits p70 ribosomal S6 kinase-1 (S6K1) — a key node in insulin resistance signaling. By suppressing S6K1, oltipraz interrupts hyperglycemia and insulin resistance at a mechanistic level. Second, the compound inhibits LXR-gamma and its downstream target SREBP-1c, directly reducing the transcriptional activation of lipogenic genes and blunting de novo fatty acid synthesis in liver tissue. These dual actions make oltipraz a mechanistically compelling candidate for NAFLD treatment.
For longevity-focused clinicians and health-conscious individuals, the significance extends beyond liver disease. NAFLD is deeply intertwined with metabolic syndrome, chronic inflammation, and accelerated biological aging. Reducing hepatic fat through AMPK activation mirrors the metabolic benefits seen with caloric restriction and exercise — well-established healthspan-extending interventions.
Caveats are important: this summary is based solely on the trial registration abstract, with no published outcome data available. The full efficacy results, safety profile, and dose-response data remain unpublished, limiting conclusions about clinical utility at this time.
Key Findings
- Oltipraz activates AMPK to inhibit S6K1, directly targeting the insulin resistance pathway underlying NAFLD.
- A second mechanism — LXR-gamma/SREBP-1c inhibition — reduces de novo fatty acid synthesis in the liver.
- Phase 3 design compared 90 mg and 120 mg oltipraz doses against placebo in non-cirrhotic NAFLD patients.
- Trial is completed, but published outcome data on liver fat reduction and safety are not yet publicly available.
- AMPK activation links oltipraz's mechanism to well-known longevity pathways, including those activated by caloric restriction.
Methodology
This was a Phase 3, placebo-controlled trial with three arms: oltipraz 90 mg, oltipraz 120 mg, and placebo, enrolling patients with NAFLD excluding those with liver cirrhosis. The trial was sponsored by PharmaKing and registered on ClinicalTrials.gov (NCT02068339). The primary outcome was liver fat reduction, though specific endpoints, sample size, and duration are not detailed in the available registration abstract.
Study Limitations
This summary is based on the trial registration abstract only; full methodology, patient demographics, outcomes, and safety data have not been published or were not accessible. The absence of published results means efficacy and safety conclusions cannot be drawn. Trial registration dates from 2014, and the gap to publication — if any exists — raises questions about result dissemination.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: